CD274 and non-small cell lung carcinoma: Chemoimmunotherapy (CIT) improved overall survival and progression-free survival (PFS) among patients with non-small cell lung cancer (NSCLC), while CIT showed limited efficacy among the subgroup with ≤49% programmed death-ligand 1 (PD-L1) expression.